Annual Shareholders Equity
$10.98 M
-$10.06 M-47.81%
31 December 2023
Summary:
Inhibikase Therapeutics annual stockholders equity is currently $10.98 million, with the most recent change of -$10.06 million (-47.81%) on 31 December 2023. During the last 3 years, it has risen by +$1.19 million (+12.20%). IKT annual shareholders equity is now -71.42% below its all-time high of $38.42 million, reached on 31 December 2021.IKT Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Shareholders Equity
-$530.60 K
-$5.63 M-110.41%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly stockholders equity is currently -$530.60 thousand, with the most recent change of -$5.63 million (-110.41%) on 30 September 2024. Over the past year, it has dropped by -$15.55 million (-103.53%). IKT quarterly shareholders equity is now -101.13% below its all-time high of $47.05 million, reached on 30 June 2021.IKT Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Shareholders Equity Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -47.8% | -103.5% |
| 3 y3 years | +12.2% | -101.2% |
| 5 y5 years | +1511.0% | - |
IKT Shareholders Equity High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -71.4% | +12.2% | -101.2% | at low |
| 5 y | 5 years | -71.4% | +344.5% | -101.1% | +89.7% |
| alltime | all time | -71.4% | +344.5% | -101.1% | +89.7% |
Inhibikase Therapeutics Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -$530.60 K(-110.4%) |
| June 2024 | - | $5.10 M(-24.8%) |
| Mar 2024 | - | $6.78 M(-38.3%) |
| Dec 2023 | $10.98 M(-47.8%) | $10.98 M(-26.9%) |
| Sept 2023 | - | $15.02 M(-22.8%) |
| June 2023 | - | $19.46 M(-23.1%) |
| Mar 2023 | - | $25.32 M(+20.4%) |
| Dec 2022 | $21.04 M | $21.04 M(-16.3%) |
| Sept 2022 | - | $25.14 M(-14.8%) |
| June 2022 | - | $29.50 M(-13.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $34.01 M(-11.5%) |
| Dec 2021 | $38.42 M(+292.6%) | $38.42 M(-11.0%) |
| Sept 2021 | - | $43.16 M(-8.3%) |
| June 2021 | - | $47.05 M(+485.5%) |
| Mar 2021 | - | $8.04 M(-17.9%) |
| Dec 2020 | $9.78 M(-317.9%) | $9.78 M(-290.9%) |
| Sept 2020 | - | -$5.13 M(+6.1%) |
| June 2020 | - | -$4.83 M(+2.7%) |
| Mar 2020 | - | -$4.70 M(+4.7%) |
| Dec 2019 | -$4.49 M(+477.1%) | -$4.49 M |
| Dec 2018 | -$778.00 K | - |
FAQ
- What is Inhibikase Therapeutics annual stockholders equity?
- What is the all time high annual shareholders equity for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual shareholders equity year-on-year change?
- What is Inhibikase Therapeutics quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly shareholders equity year-on-year change?
What is Inhibikase Therapeutics annual stockholders equity?
The current annual shareholders equity of IKT is $10.98 M
What is the all time high annual shareholders equity for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual stockholders equity is $38.42 M
What is Inhibikase Therapeutics annual shareholders equity year-on-year change?
Over the past year, IKT annual stockholders equity has changed by -$10.06 M (-47.81%)
What is Inhibikase Therapeutics quarterly stockholders equity?
The current quarterly shareholders equity of IKT is -$530.60 K
What is the all time high quarterly shareholders equity for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly stockholders equity is $47.05 M
What is Inhibikase Therapeutics quarterly shareholders equity year-on-year change?
Over the past year, IKT quarterly stockholders equity has changed by -$15.55 M (-103.53%)